Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
GnRH agonist (gonadorelin analogue)

Buserelin

Brand names: Suprefact, Suprecur

Buserelin is a gonadotrophin-releasing hormone (GnRH) agonist used in endometriosis, as part of assisted conception protocols, and in the management of hormone-responsive conditions.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Continuous administration initially stimulates then desensitises pituitary GnRH receptors, causing downregulation and a sustained fall in gonadotrophin and sex hormone production.

Prescribing in practice

  • An initial surge in sex hormones (the flare effect) occurs before suppression, which can transiently worsen symptoms and must be anticipated in hormone-sensitive disease.
  • Prolonged use induces a hypo-oestrogenic state that reduces bone mineral density, so duration is limited and add-back therapy may be considered for longer courses.
  • Effective non-hormonal contraception should be used during treatment for endometriosis as it is not a contraceptive.

Monitoring

Monitor for menopausal symptoms and, with prolonged use, consider assessment of bone mineral density.

Counselling the patient

  • You may notice a short-term worsening of symptoms when starting before they improve.
  • Expect menopausal-type effects such as hot flushes, and report troublesome symptoms.
  • Use a reliable non-hormonal method of contraception while taking this treatment.

Evidence & guidelines

GnRH agonists are an established hormonal option for endometriosis where first-line treatments are inadequate, as recognised in NICE guidance.

Reference: SmPC Suprefact / Suprecur; NICE NG131 (Prostate cancer); ESHRE IVF Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways